Sodium-glucose co-transporter 2 (SGLT2) inhibitors, also known as gliflozins, are oral antidiabetic medications that have gained prominence due to their unique mechanism of action. They are primarily used in managing type 2 diabetes mellitus but also offer significant benefits for heart failure and chronic kidney disease (CKD). These medications work by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion.
SGLT2 inhibitors, such as Empagliflozin (Jardiance) and Dapagliflozin (Farxiga), are indicated for improving glycemic control in adults with type 2 diabetes. They also reduce the risk of cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF). Additionally, these drugs slow CKD progression and reduce renal and cardiovascular events in CKD patients.
Despite their benefits, SGLT2 inhibitors come with potential side effects. Increased urinary glucose can lead to a higher risk of urinary tract infections and genital mycotic infections. There is also a risk of dehydration and hypotension due to osmotic diuresis, and rare cases of euglycemic diabetic ketoacidosis (DKA) have been reported. Patients should be monitored for acute kidney injury, although long-term use is associated with renal protection.
Patient counseling is crucial when prescribing SGLT2 inhibitors. Patients should maintain adequate hydration to prevent dehydration and hypotension. Regular monitoring of renal function and electrolytes is recommended, and patients should be informed about the signs of infections and ketoacidosis. Educating patients on these aspects helps maximize the benefits of SGLT2 inhibitors while minimizing potential risks.
